Related Experiment Video
Updated: May 3, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Soluble fms-like tyrosine kinase-1 and atherosclerosis in chronic kidney disease
11] Experimental and Clinical Research Center, Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany [2] Department of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Abstract:
Vascular endothelial growth factor (VEGF) and its cousins, such as placental growth factor, have moved into the daily clinical arena. One-step-removed regulators, such as the VEGF splice variant soluble fms-like tyrosine kinase-1 (sFlt-1), now clinically emerge. sFlt-1 keeps our corneas 'clean.' However, sFlt-1 could also cause disease, such as preeclampsia. The report by Matsui et al. on ApoE and sFlt-1 gene-deleted mice could foster important subsequent research. We are limited only by our imaginations.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Atherosclerosis I: Introduction
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology